Eyegate Pharmaceuticals (EYEG) Releases Earnings Results, Beats Expectations By $0.01 EPS
Eyegate Pharmaceuticals (NASDAQ:EYEG) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, Bloomberg Earnings reports. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.19 million.
NASDAQ EYEG traded up $0.01 during trading on Wednesday, hitting $0.43. The stock had a trading volume of 4,720,632 shares, compared to its average volume of 683,226. The company has a market cap of $13.55 million, a P/E ratio of -0.42 and a beta of 2.92. Eyegate Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $1.38.
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Eyegate Pharmaceuticals in a research report on Wednesday, September 5th.
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.